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It has been proposed that the known susceptibility genes
account only for approximately 20–25% of the hereditary risk
of getting breast cancer (Lichtenstein et al, 2000). Mutations in
the 2 major breast cancer susceptibility genes, BRCA1 and
BRCA2 (Miki et al, 1994; Wooster et al, 1995), have been found
in only about 20% of Finnish high-risk breast cancer families
(Vehmanen et al, 1997a, b; Huusko et al, 1998). Mutations in a
third gene, TP53, appear to be responsible for a minor additional
fraction of predisposition to breast cancer (reviewed in Easton,
1999). Recently, we studied the contribution of TP53 mutations
for breast cancer predisposition in Finland (Huusko et al, 1999;
Rapakko et al, 2001). Mutations were found in only 3/108
(2.8%) of BRCA1 and BRCA2 mutation-negative families. In our
studies, TP53 changes occurred exclusively in those breast cancer
families also displaying a Li–Fraumeni syndrome (LFS) or
Li–Fraumeni-like syndrome (LFL) cancer background (e.g.
sarcomas, breast cancer, leukaemia, and tumours of the central
nervous system and adrenal cortex; Garber et al, 1990), with at least
one case of bilateral disease. These observations clearly indicate that
other breast cancer susceptibility genes must also be involved
(Easton, 1999). Recently, a new susceptibility locus was identified
in chromosome region 13q21 (Kainu et al, 2000). However, it has
been estimated that this gene at the most would explain about 25%
of the remaining BRCA1/BRCA2 negative families (originating
preferentially from the central and southern parts of the country),
and that there still are additional breast cancer genes to be identified. 
Bell et al (1999) identified germline CHK2 mutations in TP53-
negative LFS and LFL families. They suggested that CHK2, which
encodes a protein kinase required for DNA damage and replication
checkpoints, is another tumour suppressor gene along with TP53
conferring predisposition to sarcoma, breast cancer and brain
tumours. After DNA damage, ATM-dependent activation of both
p53 and CHK2 occurs (reviewed in Prives and Hall, 1999). As
CHK2 is capable of phosphorylating p53 at Ser20 (Hirao et al,
2000), it appears to function as an intermediate kinase and thus
plays a key role in connecting p53 to the response to double-
stranded DNA breaks. Furthermore, CHK2 also binds to and
regulates BRCA1 (Lee et al, 2000), and the phosphorylation of
BRCA1 at Ser988 is required for the release from CHK2. Wang et al
(2000) suggested that BRCA1 could act as a scaffold protein that
organizes different types of DNA damage sensors and then serves
as an effector in response to DNA damage to coordinate repair. 
Both the association to LFS/LFL and the regulatory control 
of BRCA1, encoded by one of the 2 known major susceptibility
genes to hereditary breast cancer, makes CHK2 a good candidate
gene to search for involvement in the remaining unexplained cases
of genetic predisposition to this disease. The search for CHK2
mutations was performed on 79 Finnish families with indications
of hereditary breast cancer, in which BRCA1, BRCA2 and TP53
mutations were previously excluded (Huusko et al, 1998, 1999;
Rapakko et al, 2001). The validation of observed sequence alter-
ations was done on cohorts of suitable cancer-free and unselected
breast cancer individuals. 
MATERIALS AND METHODS 
The search for CHK2 germline mutations included all exons and
splice-site boundary regions and was performed on 79 families
with hereditary breast cancer (Table 1) originating from the Oulu
University Hospital area. From some of the cancer families
multiple affected individuals were studied. In addition, from 3 of
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gene alteration. Of the total of 98 breast cancer cases, 7 (7%) were
identified at or below age 35, 23 (24%) between ages 36–45, 49
(50%) between ages 46–60, and 19 (19%) at or above age 61.
Fifty-eight families met the criteria for moderate- to high-risk
hereditary breast cancer only, 20 families for both hereditary
breast cancer and LFL, and one family for both hereditary breast
cancer and LFS. The used criteria for hereditary breast cancer
were one or more of the following: (1) at least 3 (2 in combination
with other selection criteria) cases of breast cancer in first- or
second-degree relatives; (2) early disease onset (≤35 years alone,
or <45 in combination with other inclusion criteria); (3) bilateral
breast cancer; or (4) multiple tumours including breast cancer in
the same individual. The criteria for LFL/LFS were as in Birch et
al (1994) and Eng et al (1997). Informed consent to obtain pedi-
gree data and blood specimen for a study on cancer susceptibility
gene mutations was obtained from all patients. Control DNA
samples from blood were derived from 200 anonymous cancer-
free donors and 259 unselected breast cancer patients. Approval to
perform the study was obtained from the Ethical Board of the
Northern Ostrobotnia Health Care District and the Finnish
Ministry of Social Affairs and Health. 
DNA extraction from blood lymphocyte specimens was
performed using the standard phenol-chloroform method. The
screening for CHK2 mutations was done by conformation-sensitive
gel electrophoresis (CSGE) analysis (Huusko et al, 1998). Samples
with a band-shift were reamplified and purified with the QIAquick
PCR purification Kit (Qiagen). Sequencing analysis was performed
with the Li-Cor IR2 4200-S DNA Analysis system (Li-Cor Inc,
Lincoln, USA) and using the SequiTherm EXCEL™II DNA
Sequencing Kit-LC (Epicentre Technologies), following the
protocol provided by Li-Cor. Oligonucleotides for CSGE analysis
were synthesized based on available CHK2 genomic sequences
(Genbank accession number AL117330). Additional oligos for
CSGE and sequencing were designed by using the Primer3
software. Primer sequences and PCR conditions for CSGE and
sequencing are available upon request. 
Mutation frequency differencies between the tested groups were
analysed in Bayesian framework (Gelman et al, 1995). Unlike 
the Chi-square test, this approach provides the probabilities for the
presented hypothesis being both true and false. Furthermore, in the
Bayesian model none of the expected values are fixed, which
results in a more plausible statistical estimate. The probability
model was set up assuming that the number of mutations follow
poisson distribution with mean li = qi Ni, when the number of indi-
viduals is Ni and the mutation frequency is qi. Also, qi was assumed
to follow Beta (1, 1) = Unif (0, 1) distribution. Formally: 
xi|Ni,qi ~ Poisson (qiNi)
qi ~ Beta(1,1)
The comparisons between mutation frequencies in different
groups were performed by calculating the ratio of the frequen-
cies, Rij = qi/qj. Posterior distributions of the model parameters
were obtained by Monte Carlo Markov Chain stimulation, which
was carried out with WinBUGS 1.3 software. Also, for H0 (esti-
mating how well the frequency observed in one group equals that
in the comparison group) traditional Chi-square test calculations 
were performed, using P = 0.01 as cut-off value for statistical
significance. 
RESULTS AND DISCUSSION 
In the current study, only one missense-type mutation, Ile157 ®
Thr157, was detected within the protein-encoding region of the
CHK2 gene. This alteration was the same as that previously
reported by Bell et al (1999). In addition, 2 changes in intronic
sequences were found. No splice-site alterations were observed. 
Ile157 ® Thr157 was seen in 7/79 (8.9%) of breast cancer families
(group 1). Four of these 7 families also met the criteria for LFL. In
2 of the mutation-positive families, the mutation segregated
ambiguously with the cancer phenotype (Figure 1). In family #5, a
woman with breast cancer diagnosed at 80 carried the mutation,
whereas her unaffected 47-year-old daughter did not. However,
the proband’s unaffected 63-year-old niece was found to be a
mutation carrier. In family #7, a mother and daughter diagnosed
with breast cancer at ages 64 and 49, respectively, were both muta-
tion carriers, but the other daughter who had breast cancer at 40
was not. In addition, Ile157 ® Thr157 was found in 13/200 (6.5%) of
anonymous cancer-free blood donors (group 2), and 10/259
(3.9%) of unselected breast cancer cases (group 3). 
Using the Bayesian model, none of the probabilities for the
mutation frequencies being higher among hereditary breast cancer
patients reached 0.99, the minimum value to prove that the
observed incidence is higher than expected. The obtained proba-
bilities were 0.78 (group 1 vs 2), 0.11 (group 2 vs 3) and 0.96
(group 1 vs 3). To estimate how well the frequency observed in
one group equals that in a comparison group, traditional Chi-
square test calculations were made. The obtained values were 0.72
(P = 0.395), 2.96 (P = 0.085) and 5.53 (P = 0.019), respectively,
and thus statistically insignificant. 
As implied by the performed statistical analysis, our observa-
tion for group 2 is in contrast to the previous finding of Bell et al
(1999), who did not detect the Ile157 ® Thr157 missense mutation
among any of the 50 healthy individuals used as controls, but only
in one LFL individual with 3 primary tumours (breast, melanoma
and lung) and no other reported family history of cancer. Although
Ile157 ® Thr157 is located within the forkhead-associated (FHA)
domain, which is a highly conserved 60-amino acid protein-
interaction domain essential for activation of the CHK2 yeast
homolog Rad53 in response to DNA damage (Sun et al, 1998), the
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Table 1 Summary of the classification of the studied familiesa
Phenotype Number of families 
All studied breast cancer families 79 
Families with implications of hereditary breast cancer only 58 
Breast cancer families also fulfilling the LFL criteria 20 
Breast cancer families also fulfilling the LFS criteria 1 
aFor the inclusion criteria for each category, see the Materials and Methods section. high mutation frequency (6.5%) now observed in healthy Finnish
controls suggests that Ile157 ® Thr157 is not, at least alone, a muta-
tion resulting in predisposition to cancer. The statistical analysis
also shows that Ile157 ® Thr157 is not significantly enriched among
breast cancer patients having hereditary disease background
(including LFL). Furthermore, the ambiguous segregation in the
studied informative cancer families suggests that this alteration
is rather a polymorphism than a deleterious mutation. This
notion is also supported by the recent observation of Wu et al
(2000), who found that CHK2 protein carrying the Ile157 ®
Thr157 change has similar kinase activity, expression levels and
subcellular localization as endogenous CHK2. Also, like wild-
type CHK2, the mutant protein is activated following gamma
radiation. However, it is still unclear whether Ile157 ® Thr157 has
other effects on cellular phenotype, or possibly acts as a genetic
modifier on a breast cancer predisposing background. 
Bell and coworkers (1999) screened 4 LFS and 18 LFL cases,
and detected CHK2 mutations in 3 of the studied families (13.6%).
Therefore, a similar incidence of CHK2 mutations was initially
expected also among the 21 LFL and LFS families studied by us.
Together with the recent results of Sodha et al (2000) it now
appears that only 1 of 3 CHK2 mutations originally reported by
Bell et al (1999) is a true disease-causing change, and thus the
expected frequency of CHK2 mutations in LFS and LFL families
would be lower than was initially assumed. 
Due to the duplications of the 3¢ genomic sequences of CHK2
reported by Sodha et al (2000), atypical banding in CSGE was
observed while analysing the terminal exons 10–14, encoding
most of the protein kinase domain (data not shown). CSGE
analysis is based on homo-and heteroduplex formation between
wild-type and mutated alleles, leading to altered mobility of
different types of DNA duplexes on a denaturating polyacrylamide
gel. Körkkö et al (1998) showed that it is possible to detect more
than one kind of mismatch in the same PCR product, by the
appearance of new heteroduplex bands in CSGE. Therefore,
instead of a single band (e.g. homoduplex) indicating the lack of
mutation, genomic loci coamplified in PCR with a tested segment
of CHK2 exon 10–14 would in CSGE analysis result in additional
bands (e.g. one or more heteroduplexes). For that reason, we
concluded that screening for samples displaying a different
banding pattern in CSGE could at least provide a rough idea
whether the analysed exons contain alterations or not. The banding
patterns for exons 10–14 in our study, however, were similar in all
screened DNA samples (data not shown). To conclusively exclude
the presence of mutations in exons 10–14, this negative result
should be confirmed by using allele-specific PCR amplification.
Unfortunately, in the current study fresh sample material or breast
cancer cell lines to perform this type of analysis were not avail-
able. 
As no other mutations besides Ile157 ® Thr157 were detected
within the protein-encoding region of the CHK2 gene, our results
suggest that CHK2 does not play a significant role as predisposing
factor for hereditary breast cancer, or LFL showing excessive
cases of breast cancer, at least in the Finnish population. Larger
studies will be needed to more carefully evaluate the significance
of CHK2 alterations in predisposition to cancers related to LFS, as
well as to estimate the possible effects of founder mutations in
different populations. 
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